​Who is Alpelisib for?

For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib and fulvestrant is a precision treatment for PIK3CA mutations.

Who is Alpelisib for?

Alpelisib is suitable for specific patient populations, and the appropriate treatment option needs to be selected on an individual basis.

Alpelisib in combination with fulvestrant is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer in postmenopausal women and men. These cancers were confirmed by FDA-approved tests after endocrine-based treatment regimens failed.

Now that we know who Alpelisib is for, we'll take a closer look at the dosage and dosage to help patients use the drug correctly.

What is the dosage of Alpelisib?

Understanding the dosage and dosage of Apelix is essential for effective treatment.

1. Recommended dose

The standard dose of Alpelisib is 300 mg, which is equivalent to two 150 mg film-coated tablets. Take once daily, preferably orally with a meal, to improve absorption.

2. Duration of treatment

Apelix is continued until disease progression or unacceptable toxicity. Patient response should be closely monitored throughout treatment.

Now that we understand the dosage and administration of apelix, we will explore how well the drug works in actual treatment to help patients better understand the therapeutic potential of the drug.

How effective is the treatment of Alpelisib?

The effect of the use of Alpelisib is the focus of clinical attention, and through observation and research, it is possible to get a clearer picture of how the drug performs in actual treatment.

In patients with PIK3CA mutations, the study showed that the treatment arm with Alpelisib plus fulvestrant was consistent with the results of a blinded independent review committee (BIRC) in terms of progression-free survival (PFS) and objective response rate (ORR). This suggests that both perform equally well at slowing disease progression.

There was no significant difference in OS between the Alpelisib plus fulvestex and placebo plus fulvests groups in a prespecified overall survival (OS) analysis, suggesting that the two groups had similar effects in prolonging overall survival.

Alpelisib performed well overall in delaying disease progression, with little difference in prolonging overall survival compared to placebo. Patients are reminded to consider a variety of factors when treating.

[Warm tips] Maintaining a healthy lifestyle, including a balanced diet and moderate exercise, can have a positive impact on the treatment results; Pay attention to your mental health and maintain a positive and optimistic attitude.